Scholarlink

Purpose <p>Patients with diabetic macular oedema (DMO) are susceptible to renal injury, raising the risks of acute kidney injury (AKI) and end-stage renal disease (ESRD) associated with anti-VEGF therapies. We aimed to compare the risks of AKI and ESRD between aflibercept and ranibizumab in DMO patients, focusing on AKI and ESRD in conjunction with all-cause mortality.</p> Methods <p>A target trial emulation using the TriNetX Global Collaborative Network included adult patients with DMO who initiated treatment with aflibercept or ranibizumab in routine clinical practice. Ranibizumab exposure reflected real-world use and included both approved dosages. Patients with pre-existing ESRD or chronic kidney disease stage 5 were excluded. Propensity score matching was applied to balance demographics, comorbidities, medication use, and laboratory parameters. Time-to-event analyses were performed for AKI, ESRD, and all-cause mortality. Sensitivity analyses included application of a minimum 7-day latency window after treatment initiation to address potential temporality bias.</p> Results <p>After matching, 3411 patients were included in each treatment group (mean age, 64.0 ± 12.4 years; 51.5% male). During follow-up, aflibercept was not associated with an increased risk of AKI (hazard ratio [HR]: 0.97, 95% confidence interval [CI]: 0.89-1.06), ESRD (HR: 0.95, 95% CI: 0.83–1.09), or all-cause mortality (HR: 0.99, 95% CI: 0.89–1.10), when compared with ranibizumab. Results were consistent across subgroup and sensitivity analyses, including analyses incorporating a 7-day latency window with an HR of 1.08 (95% CI: 0.94–1.24) for AKI, and 0.89 (95% CI: 0.76–1.04) for ESRD.</p> Conclusions <p>In this multinational, real-world study, aflibercept and ranibizumab demonstrated comparable risks of AKI, ESRD and mortality among patients with DMO after adjustment for measured confounders. Given the observational design, real-world dose heterogeneity, and limitations in detailed treatment-timing data, these findings should be interpreted with caution.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of adverse renal events between ranibizumab and aflibercept in patients with diabetic macular oedema: A global network study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月22日

查看全文
  • Wan-Ju Annabelle Lee,
  • Daniel Hsiang-Te Tsai,
  • Michael Chun-Yuan Cheng,
  • Yu-Shiuan Lin,
  • Chia-Yi Lee,
  • Shih-Chieh Shao,
  • Edward Chia-Cheng Lai

摘要

Purpose

Patients with diabetic macular oedema (DMO) are susceptible to renal injury, raising the risks of acute kidney injury (AKI) and end-stage renal disease (ESRD) associated with anti-VEGF therapies. We aimed to compare the risks of AKI and ESRD between aflibercept and ranibizumab in DMO patients, focusing on AKI and ESRD in conjunction with all-cause mortality.

Methods

A target trial emulation using the TriNetX Global Collaborative Network included adult patients with DMO who initiated treatment with aflibercept or ranibizumab in routine clinical practice. Ranibizumab exposure reflected real-world use and included both approved dosages. Patients with pre-existing ESRD or chronic kidney disease stage 5 were excluded. Propensity score matching was applied to balance demographics, comorbidities, medication use, and laboratory parameters. Time-to-event analyses were performed for AKI, ESRD, and all-cause mortality. Sensitivity analyses included application of a minimum 7-day latency window after treatment initiation to address potential temporality bias.

Results

After matching, 3411 patients were included in each treatment group (mean age, 64.0 ± 12.4 years; 51.5% male). During follow-up, aflibercept was not associated with an increased risk of AKI (hazard ratio [HR]: 0.97, 95% confidence interval [CI]: 0.89-1.06), ESRD (HR: 0.95, 95% CI: 0.83–1.09), or all-cause mortality (HR: 0.99, 95% CI: 0.89–1.10), when compared with ranibizumab. Results were consistent across subgroup and sensitivity analyses, including analyses incorporating a 7-day latency window with an HR of 1.08 (95% CI: 0.94–1.24) for AKI, and 0.89 (95% CI: 0.76–1.04) for ESRD.

Conclusions

In this multinational, real-world study, aflibercept and ranibizumab demonstrated comparable risks of AKI, ESRD and mortality among patients with DMO after adjustment for measured confounders. Given the observational design, real-world dose heterogeneity, and limitations in detailed treatment-timing data, these findings should be interpreted with caution.